Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupNeuro-OncologyradiotherapyDiseaseGlioblastomaSubgroupmethylated MGMT PromoterICD10C71.-MeSHGlioblastomaSequenceTMZL75/Radiation, Glioblastoma (PID546) -|- TMZL150 after Radio-Chemo, C1 (PID547) -|- TMZL200 C2-6 (PID548)TMZL75/Radiation, Glioblastoma, C1 (PID2472) -|- C2 (PID2473) -|- C3-12 (PID2474).ChemotherapyChemo-substanceBevacizumabInterferon alpha-2aLomustineTemozolomideChemo-substanceBevacizumabInterferon alpha-2aLomustineTemozolomideChemo-substanceBevacizumabInterferon alpha-2aLomustineTemozolomideChemo-substanceBevacizumabInterferon alpha-2aLomustineTemozolomideNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronNo. Substances123Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapyTherapy phaseMaintenanceTherapy intentionpalliativeRisksAnemia Hb below 8g/dlBleedingConstipationEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueHemorrhageHepatotoxicityHypertensionIncrease AminotransferasesInfectionsLeukopeniaNeutropeniaPyrexiaSeizuresThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorBatchelor TTFriedman HSGuo CHerrlinger UStupp RWick WDiseaseGlioblastom, ECOG 0-2Glioblastom, Erst- oder Zweitredzidiv, nach Standard Radiatio und TemozolomidGlioblastom, Progress nach Chemoradiatio, ECOG 0-2Glioblastom Rezidiv nach vorangegangener Temozolomid-Therapie und Bestrahlung, ECOG 0-2neu diagnostiziertes Glioblastom, Karnofsky > 70%Neudiagnostiziertes high grade Gliom, Erstlinie, Karnofsky größer 60%OriginDepartment of Neurosurgery andNeurooncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology, South ChinaEORTC, NCICNeurology Clinic and National Center for Tumor Disease, University of Heidelberg and German Cancer Research CenteNeurooncology Working Group of the German Cancer Society, CeTeG/NOA–09The Brain Tumor Center, Duke University, Durham, USAThe REGAL Study Invetigators, REGAL StudieProtocols in Revision 10 protocols foundProtocols under revision.Bevacizumab 10 / Lomustine 90, Glioblastoma (PID2019 V1.0)Bevacizumab 10, Glioblastoma (PID549 V1.0)Interferon Alpha-2a 3Mio / Temozolomide 150, cycle 2 (PID2473 V1.1)Interferon Alpha-2a 3Mio / Temozolomide 200, Glioblastoma, Cycle 3-12 (PID2474 V1.0)Lomustine 100 / Temozolomide 100 / Radiation, Glioblastoma (PID488 V1.2)Lomustine 110, Glioblastoma (PID550 V1.1)Temozolomide 150 after Radio-Chemo, Glioblastoma cycle 1 (PID547 V1.1)Temozolomide 200 after Radio-Chemo, Glioblastoma cycle 2-6 (PID548 V1.1)Temozolomide 75 / Radiation, Glioblastoma (PID546 V1.1)Temozolomide 75 / Radiation, Glioblastoma, Cycle 1 (PID2472 V1.0)
